• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Clinical Trials Have Shown the Lack of Activity of Estramustine in Hormone Refractory Prostate Cancer, But the Drug Is Still Commonly Used Because of the Lack of Alternatives

Posted on: Friday, 3 June 2005, 12:00 CDT

DUBLIN, Ireland, June 3 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c18660 ) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )

Prostate cancer is the most common male malignancy in Western countries.

Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market.

This report details physician opinion of currently available products and disease management practice and what they require in the future.

Scope:

Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

Analysis of leading companies in the prostate cancer market and the commercial challenges and opportunities ahead.

Highlights:

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off- label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.

In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.

Reasons to Read:

Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered

Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

Plan product development to fill prostate cancer market niches as defined by practicing physicians

For more information visit http://www.researchandmarkets.com/reports/c18660

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCHAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com

Research and Markets

CONTACT: Laura Wood, Senior Manager of Research and Markets,press@researchandmarkets.com , or fax, +353-1-4100-980

Web site: http://www.researchandmarkets.com/reports/c18660

Source: PRNewswire

More News in this Category